SIMIPEX XR pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

simipex xr pramipexole dihydrochloride monohydrate 3.75 mg modified release tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3.75 mg - tablet, modified release - excipient ingredients: silicon dioxide; hypromellose; magnesium stearate; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIMIPEX XR pramipexole dihydrochloride monohydrate 0.75 mg modified release tablet blister pacl Australia - English - Department of Health (Therapeutic Goods Administration)

simipex xr pramipexole dihydrochloride monohydrate 0.75 mg modified release tablet blister pacl

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.75 mg - tablet, modified release - excipient ingredients: hypromellose; silicon dioxide; magnesium stearate; calcium hydrogen phosphate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIFROL ER pramipexole dihydrochloride monohydrate 4.5 mg extended-release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sifrol er pramipexole dihydrochloride monohydrate 4.5 mg extended-release tablet blister pack

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 4.5 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; hypromellose; maize starch; carbomer 941; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIFROL ER pramipexole dihydrochloride monohydrate 3 mg extended-release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sifrol er pramipexole dihydrochloride monohydrate 3 mg extended-release tablet blister pack

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3 mg - tablet, modified release - excipient ingredients: maize starch; hypromellose; colloidal anhydrous silica; carbomer 941; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIFROL ER  pramipexole dihydrochloride monohydrate 1.5 mg extended-release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sifrol er pramipexole dihydrochloride monohydrate 1.5 mg extended-release tablet blister pack

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; maize starch; hypromellose; carbomer 941 - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIFROL ER pramipexole dihydrochloride monohydrate 0.75 mg extended-release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sifrol er pramipexole dihydrochloride monohydrate 0.75 mg extended-release tablet blister pack

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.75 mg - tablet, modified release - excipient ingredients: maize starch; colloidal anhydrous silica; hypromellose; carbomer 941; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIFROL ER  pramipexole dihydrochloride monohydrate 0.375 mg extended-release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sifrol er pramipexole dihydrochloride monohydrate 0.375 mg extended-release tablet blister pack

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.375 mg - tablet, modified release - excipient ingredients: maize starch; hypromellose; magnesium stearate; colloidal anhydrous silica; carbomer 941 - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIFROL ER pramipexole dihydrochloride monohydrate 3.75 mg extended-release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sifrol er pramipexole dihydrochloride monohydrate 3.75 mg extended-release tablet blister pack

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3.75 mg - tablet, modified release - excipient ingredients: carbomer 941; colloidal anhydrous silica; maize starch; hypromellose; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIFROL ER pramipexole dihydrochloride monohydrate 2.25 mg extended-release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

sifrol er pramipexole dihydrochloride monohydrate 2.25 mg extended-release tablet blister pack

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; maize starch; colloidal anhydrous silica; carbomer 941 - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

SIMIPEX pramipexole dihydrochloride monohydrate 1 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

simipex pramipexole dihydrochloride monohydrate 1 mg tablet blister pack

arrotex pharmaceuticals pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: pregelatinised maize starch; mannitol; microcrystalline cellulose; povidone; purified talc; magnesium stearate - the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.,the symptomatic treatment of primary restless legs syndrome.